These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 25419975)

  • 1. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging.
    Lee EK; Choi SH; Yun TJ; Kang KM; Kim TM; Lee SH; Park CK; Park SH; Kim IH
    Korean J Radiol; 2015; 16(6):1341-8. PubMed ID: 26576125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
    Kim BR; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    PLoS One; 2016; 11(11):e0166096. PubMed ID: 27835666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.
    Kim SK; Kim TM; Lee ST; Lee SH; Heo DS; Kim IH; Kim DG; Jung HW; Choi SH; Lee SH; Park CK
    J Clin Neurosci; 2016 Dec; 34():145-150. PubMed ID: 27475318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
    Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH
    Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
    Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
    Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
    Oh SW; Jee TK; Kong DS; Nam DH; Lee JI; Seol HJ
    Acta Neurochir (Wien); 2014 Apr; 156(4):641-51. PubMed ID: 24553726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
    Goda JS; Lewis S; Agarwal A; Epari S; Churi S; Padmavati A; Gupta T; Shetty P; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2015 Aug; 135():46-53. PubMed ID: 26038275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
    Rhee DJ; Kong DS; Kim WS; Park KB; Lee JI; Suh YL; Song SY; Kim ST; Lim DH; Park K; Kim JH; Nam DH
    Clin Neurol Neurosurg; 2009 Nov; 111(9):748-51. PubMed ID: 19716649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
    Saito T; Sugiyama K; Ikawa F; Yamasaki F; Ishifuro M; Takayasu T; Nosaka R; Nishibuchi I; Muragaki Y; Kawamata T; Kurisu K
    World Neurosurg; 2017 Jan; 97():21-26. PubMed ID: 27693246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.
    Chiang KL; Chang KP; Lee YY; Huang PI; Hsu TR; Chen YW; Chang FC; Wong TT
    Childs Nerv Syst; 2010 Aug; 26(8):1035-41. PubMed ID: 20217098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.